TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,199,043 | -42.3% | 245,978 | -0.9% | 0.00% | -100.0% |
| Q2 2023 | $3,811,523 | -21.8% | 248,146 | +14.5% | 0.00% | 0.0% |
| Q1 2023 | $4,875,135 | +8.7% | 216,769 | +1.7% | 0.00% | 0.0% |
| Q4 2022 | $4,484,080 | -15.0% | 213,223 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $5,276,000 | +14.3% | 214,118 | +12.4% | 0.00% | 0.0% |
| Q2 2022 | $4,615,000 | -18.9% | 190,501 | -13.7% | 0.00% | 0.0% |
| Q1 2022 | $5,689,000 | -17.5% | 220,787 | -0.6% | 0.00% | 0.0% |
| Q4 2021 | $6,894,000 | +27.4% | 222,088 | -0.5% | 0.00% | 0.0% |
| Q3 2021 | $5,413,000 | +82.3% | 223,250 | +9.7% | 0.00% | 0.0% |
| Q2 2021 | $2,969,000 | -42.4% | 203,454 | -1.4% | 0.00% | 0.0% |
| Q1 2021 | $5,154,000 | -3.4% | 206,412 | +5.5% | 0.00% | 0.0% |
| Q4 2020 | $5,334,000 | – | 195,689 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |